NYSE:DVA Davita Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Davita Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $85.12 -2.20 (-2.52 %) (As of 09/21/2020 12:00 AM ET) Add Compare Share Today's Range$82.52Now: $85.12▼$86.4650-Day Range$81.73MA: $86.16▼$91.8452-Week Range$54.08Now: $85.12▼$92.67Volume1.40 million shsAverage Volume1.30 million shsMarket Capitalization$10.38 billionP/E Ratio13.43Dividend YieldN/ABeta1.2 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services; vascular access services; clinical research programs; physician services; and comprehensive care services. As of December 31, 2018, it provided dialysis and administrative services in the United States through a network of 2,664 outpatient dialysis centers serving approximately 202,700 patients; and operated 241 outpatient dialysis centers located in 9 countries outside of the United States serving approximately 25,000 patients. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was founded in 1994 and is headquartered in Denver, Colorado.Read More Beat the Market (BTM) Rank™ 1.1 Analyst's Opinion Consensus RatingDavita has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 6 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $73.40, Davita has a forecasted downside of 13.8% from its current price of $85.12.Amount of Analyst CoverageDavita has only been the subject of 2 research reports in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesDavita has received 462 “outperform” votes. (Add your “outperform” vote.)Underperform VotesDavita has received 524 “underperform” votes. (Add your “underperform” vote.)Community SentimentDavita has received 53.14% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Davita and other stocks. Vote “Outperform” if you believe DVA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe DVA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldDavita does not currently pay a dividend.Dividend GrowthDavita does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Davita insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $17,650,298.00 in company stock.Percentage Held by InsidersOnly 1.00% of the stock of Davita is held by insiders.Percentage Held by Institutions91.56% of the stock of Davita is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Davita are expected to grow by 5.78% in the coming year, from $6.75 to $7.14 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Davita is 13.43, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 18.37.Price to Earnings Ratio vs. SectorThe P/E ratio of Davita is 13.43, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.63.Price to Book Value per Share RatioDavita has a P/B Ratio of 4.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.1Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.26 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSE Industry Miscellaneous health & allied services, not elsewhere classified Sub-IndustryHealth Care Services SectorMedical Current SymbolNYSE:DVA Previous Symbol CUSIP23918K10 CIK927066 Webwww.davita.com Phone720-631-2100Debt Debt-to-Equity Ratio3.38 Current Ratio1.35 Quick Ratio1.33Price-To-Earnings Trailing P/E Ratio13.43 Forward P/E Ratio12.61 P/E GrowthN/A Sales & Book Value Annual Sales$11.39 billion Price / Sales0.91 Cash Flow$10.94 per share Price / Cash Flow7.78 Book Value$18.10 per share Price / Book4.70Profitability EPS (Most Recent Fiscal Year)$5.40 Net Income$810.98 million Net Margins7.20% Return on Equity40.78% Return on Assets5.29%Miscellaneous Employees65,000 Outstanding Shares121,989,000Market Cap$10.38 billion Next Earnings Date11/3/2020 (Estimated) OptionableOptionable $85.12 -2.20 (-2.52 %) (As of 09/21/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive DVA News and Ratings via Email Sign-up to receive the latest news and ratings for DVA and its competitors with MarketBeat's FREE daily newsletter. Davita (NYSE:DVA) Frequently Asked Questions How has Davita's stock price been impacted by Coronavirus (COVID-19)? Davita's stock was trading at $74.87 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, DVA stock has increased by 13.7% and is now trading at $85.12. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Davita? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Davita in the last year. There are currently 6 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Davita. When is Davita's next earnings date? Davita is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020. View our earnings forecast for Davita. How were Davita's earnings last quarter? Davita Inc (NYSE:DVA) released its quarterly earnings results on Thursday, July, 30th. The company reported $1.95 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $1.30 by $0.65. The firm earned $2.88 billion during the quarter, compared to analyst estimates of $2.91 billion. Davita had a return on equity of 40.78% and a net margin of 7.20%. View Davita's earnings history. What guidance has Davita issued on next quarter's earnings? Davita issued an update on its FY20 earnings guidance on Thursday, July, 30th. The company provided earnings per share (EPS) guidance of $6.25-$6.75 for the period, compared to the Thomson Reuters consensus estimate of $6.11. The company issued revenue guidance of $11.5-$11.7 billion, compared to the consensus revenue estimate of $11.70 billion. What price target have analysts set for DVA? 8 brokers have issued 12 month price targets for Davita's shares. Their forecasts range from $57.00 to $100.00. On average, they anticipate Davita's stock price to reach $73.40 in the next year. This suggests that the stock has a possible downside of 13.8%. View analysts' price targets for Davita. Are investors shorting Davita? Davita saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 5,710,000 shares, an increase of 12.2% from the August 15th total of 5,090,000 shares. Based on an average daily trading volume, of 973,800 shares, the short-interest ratio is presently 5.9 days. Currently, 4.7% of the company's shares are short sold. View Davita's Short Interest. Who are some of Davita's key competitors? Some companies that are related to Davita include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), Amedisys (AMED), Chemed (CHE), LHC Group (LHCG), AMN Healthcare Services (AMN), R1 RCM (RCM), CorVel (CRVL), MEDNAX (MD), The Providence Service (PRSC), Tivity Health (TVTY), Cross Country Healthcare (CCRN) and Interpace Diagnostics Group (IDXG). View all competitors. What other stocks do shareholders of Davita own? Based on aggregate information from My MarketBeat watchlists, some companies that other Davita investors own include CA (CA), BlackRock (BLK), Chipotle Mexican Grill (CMG), Endologix (ELGX), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), United Rentals (URI), AT&T (T), AbbVie (ABBV) and AutoZone (AZO). Who are Davita's key executives? Davita's management team includes the following people: Mr. Kent J. Thiry, Chairman & CEO (Age 63)Mr. Joel Ackerman, Chief Financial Officer (Age 54)Mr. James K. Hilger, Chief Accounting Officer (Age 57)Ms. Kathleen Alyce Waters, Chief Legal Officer (Age 51)Mr. Javier J. Rodriguez, Chief Exec. Officer of DaVita Kidney Care (Age 48) What is Davita's stock symbol? Davita trades on the New York Stock Exchange (NYSE) under the ticker symbol "DVA." Who are Davita's major shareholders? Davita's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.28%), Bank of New York Mellon Corp (2.22%), Par Capital Management Inc. (1.71%), Robeco Institutional Asset Management B.V. (1.38%), LSV Asset Management (0.82%) and AQR Capital Management LLC (0.65%). Company insiders that own Davita stock include Charles Berg, John M Nehra, Kent J Thiry, Pamela M Arway, Paul J Diaz and R Ted Weschler. View institutional ownership trends for Davita. Which major investors are selling Davita stock? DVA stock was sold by a variety of institutional investors in the last quarter, including Par Capital Management Inc., Vanguard Group Inc., First Trust Advisors LP, Canada Pension Plan Investment Board, AJO LP, Sumitomo Mitsui Trust Holdings Inc., Prudential Financial Inc., and Glenmede Trust Co. NA. Company insiders that have sold Davita company stock in the last year include Charles Berg, John M Nehra, Kent J Thiry, Pamela M Arway, Paul J Diaz, and R Ted Weschler. View insider buying and selling activity for Davita. Which major investors are buying Davita stock? DVA stock was bought by a variety of institutional investors in the last quarter, including State of Michigan Retirement System, LSV Asset Management, Bridgeway Capital Management Inc., AQR Capital Management LLC, Todd Asset Management LLC, Bellevue Group AG, Robeco Institutional Asset Management B.V., and Teachers Retirement System of The State of Kentucky. View insider buying and selling activity for Davita. How do I buy shares of Davita? Shares of DVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Davita's stock price today? One share of DVA stock can currently be purchased for approximately $85.12. How big of a company is Davita? Davita has a market capitalization of $10.38 billion and generates $11.39 billion in revenue each year. The company earns $810.98 million in net income (profit) each year or $5.40 on an earnings per share basis. Davita employs 65,000 workers across the globe. What is Davita's official website? The official website for Davita is www.davita.com. How can I contact Davita? Davita's mailing address is 2000 16TH STREET, DENVER CO, 80202. The company can be reached via phone at 720-631-2100 or via email at [email protected] This page was last updated on 9/22/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
